Targeting antibodies dissociate from drug delivery liposomes during blood circulation
Journal of Controlled Release · 2025-03 · 379 · 982-992
DOI: 10.1016/j.jconrel.2025.01.047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-03. Verfasst von Unnur J Björgvinsdóttir und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark. Hauptthemen laut MEDLINE: Liposomes, Drug Delivery Systems, Antibodies. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Despite three decades of intense research, active targeting of liposomes have not been successfully achieved in a clinical setting. A potential explanation is that the clinically used liposomes lose their targeting abilities upon circulation. Here, we investigated if DSPE-PEG anchored antibody-based targeting ligands dissociate from clinically relevant drug delivery liposomes during circulation in mice. We found that during 4 h of circulation, a significant fraction of the liposomes lose all targeting ligands, while the liposomes with some targeting ligands remaining on their surface, show a > 50 % reduction in surface density of ligands. This was detected irrespective of antibody format (IgG, Fab, F(ab’)2), ability to interact with Fc receptors or linking chemistry. Dissociation of targeting antibodies did however not take place when incubating liposomes in serum, but required an in vivo setup, demonstrating that in vitro setups are unsuitable for quantifying such liposome disassembly processes. The observation unravels a problem that researchers developing targeted drug delivery vehicles should take into account when designing novel formulations. • Association of targeting ligands with stealth liposomes was studied using a single particle assay. • Roughly half of the targeting ligands dissociated from liposomes after 4 h blood circulation. • Size of the ligand had limited impact on the extent of dissociation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark.
- Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark. Electronic address: tlan@dtu.dk.
- Biotherapeutic Engineering and Drug Targeting, Department of Health Technology, Technical University of Denmark (DTU), Kgs. Lyngby, Denmark. Electronic address: rasmus.munter@croda.com.
Zitieren
APA
Björgvinsdóttir, U. J., Larsen, J. B., Bak, M., Andresen, T. L., & Münter, R. (2025). Targeting antibodies dissociate from drug delivery liposomes during blood circulation. Journal of Controlled Release, 379, 982-992. https://doi.org/10.1016/j.jconrel.2025.01.047
Vancouver
Björgvinsdóttir UJ, Larsen JB, Bak M, Andresen TL, Münter R. Targeting antibodies dissociate from drug delivery liposomes during blood circulation. Journal of Controlled Release. 2025;379:982-992. doi:10.1016/j.jconrel.2025.01.047
BibTeX
@article{Bjrgvinsdttir2025,
author = {Björgvinsdóttir, Unnur J and Larsen, Jannik B and Bak, Martin and Andresen, Thomas L and Münter, Rasmus},
title = {Targeting antibodies dissociate from drug delivery liposomes during blood circulation},
journal = {Journal of Controlled Release},
year = {2025},
volume = {379},
pages = {982--992},
doi = {10.1016/j.jconrel.2025.01.047}
}
EUVIMED